Evidence map›Paper›PMID 41903547›Full record

ArticleCell reports. Medicine2026

Role of dopamine in the development of impaired counterregulation and impaired awareness of hypoglycemia.

Erica Macon, Micah H Devore, Adriana Vieira de Abreu, Rahul Agrawal, Sunny Sharma, Parker Howe, Ashlee Marksbury, Mason Wooten, Evan Brockman, Owen Chan and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Erica MaconDivision of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, University of Kentucky, Lexington, KY, USA; Department of Animal Science, College of Agriculture and Life Sciences, Texas A&M University, College Station, TX, USA.
Micah H DevoreDivision of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, University of Kentucky, Lexington, KY, USA.
Adriana Vieira de AbreuDivision of Endocrinology, Metabolism and Diabetes, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.
Rahul AgrawalDivision of Endocrinology, Metabolism and Diabetes, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.
Sunny SharmaDivision of Endocrinology, Metabolism and Diabetes, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.
Parker HoweDivision of Endocrinology, Metabolism and Diabetes, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.
Ashlee MarksburyDivision of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, University of Kentucky, Lexington, KY, USA.
Mason WootenDivision of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, University of Kentucky, Lexington, KY, USA.
Evan BrockmanDivision of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, University of Kentucky, Lexington, KY, USA.
Owen ChanDivision of Endocrinology, Metabolism and Diabetes, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.
Simon J FisherDivision of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, University of Kentucky, Lexington, KY, USA. Electronic address: simon.fisher@uky.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For people with diabetes, the syndrome of hypoglycemia-associated autonomic failure (HAAF) is composed of a blunted counterregulatory response (CRR) and impaired awareness of hypoglycemia (IAH). The objective herein is to identify a drug that might correct these components of HAAF. A rodent model of HAAF was developed to induce both impaired CRR and IAH (blunted food intake response to hypoglycemia). A drug screen identifies the dopamine antagonist, metoclopramide (MET), that prevents the development of HAAF. Additionally, following the induction of HAAF, MET restores normal awareness and CRRs. Conversely, the dopamine receptor agonist (bromocriptine), when administered centrally, induces HAAF. Finally, dopaminergic modulation of the ventral tegmental area (VTA) induces reciprocal changes in CRR to hypoglycemia with matching changes in VTA dopaminergic gene expression. These data identify dopamine signaling as a critical mediator of HAAF and dopamine antagonism as a potential treatment strategy.

Indexed as

DopamineHypoglycemiaAnimalsDopamine AntagonistsMaleMetoclopramideRatsVentral Tegmental AreaDopamineDopamine AntagonistsMetoclopramidebraincognitioncounterregulationdiabetesdopaminehypoglycemiainsulinmetabolismmetoclopramiderat

Identifiers

PMID41903547
PMCPMC13130643

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.